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Abstract 
Review on the translocation t(2;11)(p23;q12.3) 
EEF1G/ALK involving EEF1G (alias, eukaryotic 
translation elongation factor 1 gamma) gene and 
ALK (alias, anaplastic lymphoma kinase) gene. The 
novel fusion gene and correspondent chimeric 
protein were observed in pediatric anaplastic large 
cell lymphoma (ALCL) patients.  EEF1G/ALK 
translocation carries an unfavorable prognosis. 
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Clinics and pathology 
Disease 
Anaplastic large cell lymphoma (ALCL), CD30-
positive, ALK-positive 
Note 
Anaplastic lymphoma kinase (ALK)-positive 
anaplastic large cell lymphoma, alias ALK+ ALCL, 
is a T-cell peripheral lymphoma characterized by 
many genomic aberrations and chromosomal 
rearrangements that make the cellular karyotype 
much complicated. It consists of a proliferation of 
usually large, pleomorphic, T-lymphocytes with 
strong expression of the cytokine receptor CD30 
(CD30+), with abundant cytoplasm and the presence 
of some translocation and rearrangements involving 
the ALK gene with 2p23/ALK aberrations well 
know, such as the classic t(2;5)(p23;q35) 
NPM1/ALK rearrangement, and others less know. 
These multiple partner fusion genes are transcribed 
and also translated in several fusion protein variants 
(Palacios et al., 2017; van der Krogt et al., 2017; van 
Krieken, 2017; Stein et al., 2000; 
http://codes.iarc.fr). 
Epidemiology 
ALK+ ALCL predominantly affects young male 
patients and in one study 28 pediatric patients were 
tested for the presence of the chimeric EEF1G/ALK 
fusion gene and is emerged that only four of them 
(4/28, i.e. 14,29%) shown a different variant by 
common NPM1/ALK rearrangement (that represent 
instead 85,71% of samples) and only two of whom 
(2/28, i.e. 7,14%) shown the chimeric EEF1G/ALK 
fusion (Palacios et al., 2017; Stein et al., 2000). 
Prognosis 
The prognosis is very poor. In fact, patients 
expressing EEF1G/ALK fusion gene have shown an 
unfavorable clinical course with fatal outcome. 
Cytogenetics 
Cytogenetics molecular 
In ALK+ ALCL was observed that the major fusion 
partner of ALK is nucleophosmin 1 (NPM1) which 
results in the translocation t(2;5)(p23;q35) and 
aberrant production of the fusion protein 
NPM1/ALK (Morris et al., 1994; Palacios et al., 
2017) but other different partners has been 
identified, such as  TMP3, TFG, ATIC, CLTCL, 
MSN, MYH9, TRAF1 and EEF1G (Hallberg and 
Palmer, 2013; Stein et al., 2000).  
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Figure.1 Schematic representation of the eEF1G, ALK and eEF1G/ALK proteins.  In the picture are shown the subcellular 
localization of the three proteins and their main role. The native ALK protein is a transmembrane receptor ligand-dependent while 
the fusion of its kinase domain with a portion of eEF1G protein brings the kinase domain to be cytoplasmic, ligand-independent 
and constitutively active (for more details see the text). 
 
Remarkably, any fusion with an alternative partner 
leads to an aberrant constitutive activation of the 
catalytic domain of ALK through homodimerization 
(Palacios et al., 2017; Bischof et al., 1997). 





Alias: Eukaryotic translation elongation factor 1 
gamma, EF1G, GIG35, PRO1608, EEF1γ, EEF1Bγ, 
EEF-1B Gamma, EF-1-Gamma, Elongation Factor 
1-Gamma, Translation Elongation Factor EEF-1 
Gamma Chain, Pancreatic Tumor-Related Protein  
Eukaryotic translation elongation factor 1 gamma, 
alias eEF1G, is a protein that play a main function in 
the elongation step of translation process but also 
cover numerous moonlighting roles. It is expressed 
ubiquitously in human tissues and often it is found 
over-expressed in human cancer samples and cancer 
cell lines. 
DNA/RNA 
EEF1G (Eukaryotic Translation Elongation Factor 1 
Gamma) is a protein coding gene with 10 exons and 
a length of 14388 bp (RefSeq  NC_000011.10). Its 
transcript is 1446 bp long (RefSeq NM_001404.5) 
but was observed five splice variants and nine 
pseudogenes probably originated by 
retrotransposition. 
Protein 
eEF1G is formed by 437 amino acids (RefSeq 
NP_001395.1), it has a molecular weight of 50.12 
kDa and it is a multi-domain protein which consist 
of three main domains: from the amino to carboxyl 
half terminal there are a glutathione S-transferase 
(GST)-like N-terminus domain (NT-eEF1G), a 
glutathione S-transferase (GST)-like C-terminus 
domain (CT-eEF1G) and a conserved C-terminal 
domain (CD-eEF1G)(Achilonu et al.,2014).  
eEF1G is a subunit of the eukaryotic elongation 
factor-1 complex named eEF1H that result by the 
aggregation of different proteins that play a central 
role in peptide elongation during eukaryotic protein 
biosynthesis. The physiological role of eEF1G is still 
not well defined, however eEF1G seems to be 
necessary for guarantee the stability to entire eEF1H 
complex and to stimulate the activity of the eEF1B2 
subunit during the elongation step of translation 
(Mansilla et al., 2002). However, are known that it 
has multiple non-canonical roles (moonlighting 
roles) inside the cell such as the interaction with 
cytoskeleton and binding with various mRNA and 
several proteins, comprise membrane-bound 
receptors (Coumans et al., 2014; Corbi et al., 2010; 




Alias: anaplastic lymphoma receptor tyrosine kinase, 
anaplastic lymphoma kinase (Ki-1), CD246, 
NBLST3 
DNA/RNA 
ALK (anaplastic lymphoma kinase) gene is 
composed by 29 exons (RefSeq NC_000002) and its 
transcript is 6240 nt long (RefSeq NM_004304). 
Protein 
ALK is formed by 1620 amino acids (RefSeq 
NP_004295) and it has a molecular weight of 177 
kDa. It is a transmembrane receptor tyrosine kinase 
of the insulin receptor superfamily  and it is 
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composed of several domains, i.e. an extracellular 
region (with meprin, A-5 protein, and receptor 
protein-tyrosine phosphatase mu domains, alias 
MAM domains), a transmembrane domain and an 
intracellular region with a tyrosine kinase domain 
(Allouche M, 2010).  
The native ALK protein is found to be expressed 
during the development and at a weaker level in adult 
central and peripheral nervous system, but it cannot 
be detected in hematopoietic cells (Iwahara et al., 
1997). The function of ALK receptor is poorly 
understood but it is supposed that it may has a role 
in the development and maintenance of central and 
peripheral nervous system (Allouche M, 2010; 
Allouche M, 2007). 




It was observed in some ALK+ ALCL pediatric 
patients the presence of an in-frame fusion transcript 
between an intronic region among exons 8 and 9 of 
EEF1G with the middle part of exon 20 of ALK. The 
resulting novel fusion chimeric gene 
5'EEF1G/3'ALK was revealed to be a coding-gene 
(van der Krogt et al., 2017).  
On the contrary, other authors found EEF1G/ALK 
transcripts in a tumor sample originated by the 
genomic fusion of the exon 6 of EEF1G with the 
exon 20 of ALK.  
The presence of the chimera EEF1G/ALK was not 
observed in vitro in the corresponding cancer SupM2 




The EEF1G/ALK fusion gene encodes a chimeric 
protein of 780 amino acids with a molecular mass of 
87 kDa. Its amino acidic structure include the N-
terminal GST-like domain of EEF1G (residues 1-
225) and the intracellular tail containing the protein 
tyrosine kinase (PTK) domain of ALK (resides 226-
780) (Palacios et al., 2017). In another study by other 
authors the chimeric eEF1G/ALK protein was 
described with some structural differences and it was 
reported that it is 857 amino acids long (van der 
Krogt et al., 2017). The chimeric protein 
eEF1G/ALK is a constitutively active protein as 
demonstrated by analysis and this is due to its own 
probable homodimerization followed by the kinase 
activation (Palacios et al., 2017; van der Krogt et al., 
2017; van Krieken, 2017; Allouche M, 2007). 
 
 
Figure.2 Schematic representation of the eEF1G, ALK and eEF1G/ALK protein structures.  In the upper side of the image 
there are the structures with also the main structural domains both eEF1G protein and ALK protein. In the bottom side of the 
image are reported two proposed structures by different authors: (1) eEF1G/ALK fusion protein with complete GST C-terminal 
domain and GST N-terminal domain of eEF1G fused with the kinase domain of ALK (Palacios et al., 2017) and (2) eEF1G/ALK 
fusion protein with complete C-terminal domain, GST C-terminal domain and with a partial GST N-terminal domain of eEF1G 
fused with the kinase domain of ALK (van der Krogt et al., 2017) (reworked by Palacios et al., 2017; van der Krogt et al., 2017) 
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Furthermore, was revealed that expression of 
EEF1G/ALK can give a cytokine-independent 
growth to the cancer cells. However, its biological 
activities, its oncogenic potential and its roles in 
proliferation and cancer aggressiveness are still poor 
understood although it is supposed that eEF1G-ALK 
fusion protein has a cell-transforming activity due to 
the activation of ALK kinase by the GST domain of 
EEF1G (Palacios et al., 2017). 
Expression / Localisation 
EEF1G/ALK was found only in the cytoplasm 
(Palacios et al., 2017). 
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